Overview

A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC

Status:
Terminated
Trial end date:
2020-05-12
Target enrollment:
Participant gender:
Summary
This is a phase Ib,single arm,open label study evaluating the safety and efficacy of CT053PTSA in patients with advanced and metastatic renal cell cancer who have progressed from previous treatment
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.